Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer’s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
